Fund moves

Pfizer (PFE): Brandes Investment Partners, LP added to its stake +370K shares

Brandes Investment Partners, LP added to its stake in Pfizer, per its Q3 2025 13F.

8.41M
Shares reported · +370K vs prior quarter
1.7%
Disclosed portfolio weight
$214M
Reported value
Holdings as of
Sep 30, 2025
Filed
Nov 14, 2025

What stands out in this filing

  • 8,042,709 shares in Q2 2025, 8,412,771 now (+4.6% in share count).
  • Reported at $214M, 1.72% of the portfolio value in this 13F filing.
  • 79 other tracked managers reported the same kind of change for Q3 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 17, 2025Congress · 1 personMembers of Congress: 2 purchases
  2. Sep 16, 2025FDAFDA drug approval: Ibrance
  3. Sep 16, 2025FDAFDA drug approval: Ibrance
  4. Oct 16, 2025FDAFDA drug approval: Xeljanz
  5. Nov 4, 2025Company filing · Form 8-K · ResultsReported its results

What came next

  1. Nov 18, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  2. Nov 26, 2025Government · Federal Register noticeForeign-Trade Zone (FTZ) 43; Authorization of Limited Production Activity; Pfizer, Inc.; (Pharmaceutical Intermediate Product); Kalamazoo, Michigan
  3. Dec 12, 2025Government · Federal Register noticePfizer Inc., U.S. Agent for King Pharmaceuticals LLC, et al.; Withdrawal of Approval of 20 Abbreviated New Drug Applications
  4. Dec 19, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  5. Dec 31, 2025CongressDisclosed sale of PFE — reported range $100,001 - $250,000
  6. Jan 2, 2026Government · Federal Register noticeRevocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
  7. Jan 23, 2026Federal contract · $22K obligatedDepartment of Defense awarded Pfizer: $22K obligated to date
  8. Jan 26, 2026Federal contract · $9K obligatedDepartment of Defense awarded Pfizer: $9K obligated to date
  9. Jan 29, 2026Federal contract · $3K obligatedDepartment of Defense awarded Pfizer: $2.8K obligated to date
  10. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  11. Feb 9, 2026Government · Federal Register ruleAir Plan Approval; Connecticut; Revised Format for Materials Incorporated by Reference
  12. Feb 10, 2026CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  13. Feb 18, 2026Federal contract · $8K obligatedDepartment of Defense awarded Pfizer: $8.2K obligated to date
  14. Feb 19, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  15. Feb 24, 2026FDAFDA drug approval: Braftovi
  16. Feb 24, 2026FDAFDA drug approval: Braftovi
  17. Feb 26, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
  18. Mar 6, 2026FDAFDA drug approval: Xeljanz
  19. Mar 6, 2026FDAFDA drug approval: Xeljanz XR
  20. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Pfizer

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

How this filing works

Explore the data

Common questions

What does this filing report about Pfizer (PFE) stock?

Brandes Investment Partners, LP added to its stake in Pfizer, per its Q3 2025 13F. Now 8.41M shares, $214M reported value, 1.7% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Sep 30, 2025. Filed: Nov 14, 2025.

What stands out in this filing?

8,042,709 shares in Q2 2025, 8,412,771 now (+4.6% in share count). Reported at $214M, 1.72% of the portfolio value in this 13F filing. 79 other tracked managers reported the same kind of change for Q3 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Pfizer recently?

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the PFE page.

Does this mean PFE stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data